3 - OSR Holdings, Inc. (0001840425) (Issuer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

10-Q - OSR Holdings, Inc. (0001840425) (Filer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

DEF 14A - OSR Holdings, Inc. (0001840425) (Filer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

PRE 14A - OSR Holdings, Inc. (0001840425) (Filer)

BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conducive to Woori IO's commercialization strategy. The FDA has clarified that consumer wearable products providing non-medical, wellness-oriented health insights—when appropriately labeled and marketed—generally fall outside the scope of m

BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO). This appointment strategically strengthens Vaximm's leadership with deep, long-standing expertise in the company's core technology. Dr. Wieckowski brings multidisciplinary experience spanning immunology and advanced data science, a profile uniquely poised to integrate reproducible analytical workflows and data-driven strategies to acc

BELLVUE, Wash., Jan. 12, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH) today announced that its Swiss biotechnology subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe AG confirming BCM Europe's interest in entering a global exclusive licensing transaction for VXM01, Vaximm's lead immunotherapy candidate. Under the terms of the binding term sheet, BCM Europe intends to establish and manage a dedicated investment vehicle, anchored by a strategic investor, tentatively named BCM Decentralized Science Investors I, LP (the "Fund"), which would act as th

Company advancing dual clinical pathways, including a Samsung-supported PoC trial in Korea and a planned U.S. FDA trial with a leading California research university BELLEVUE, Wash., Dec. 19, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings"), a global healthcare holding company, today announced that the shareholders of Woori IO Co., Ltd. ("Woori IO"), a leading Korean medical device innovator in noninvasive glucose monitoring technology, approved a share exchange at an Extraordinary General Meeting ("EGM") held at Woori IO's headquarters in Jeonju, Korea. The approved share exchange will result in Woori IO becoming a wholly-owned subsidiary of OSR Holdings Co., Ltd. ("OS

MIAMI, Dec. 10, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 & 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Presenting Day 1 – Today - December 10, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already regis

MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 & 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayDecember 10, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go

BELLEVUE, Wash., Dec. 2, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH) today provided an update regarding the previously announced non-binding term sheet between its subsidiary, Vaximm AG, and BCM Europe AG ("BCME"). The parties have agreed to shorten the exclusivity period from six months to three months, reflecting the strong alignment and confidence between Vaximm and BCME in advancing a definitive exclusive global licensing agreement for VXM01, Vaximm's first-in-class orally administered cancer immunotherapy platform. Under the updated timeline, Vaximm and BCME now

BELLEVUE, Wash., Dec. 1, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company advancing biomedical innovations to improve health and wellness worldwide, today announced that management will present at the upcoming Emerging Growth Conference. This presentation will provide investors and analysts with an updated overview of OSR Holdings' diversified healthcare platforms and strategic growth initiatives. Virtual Presentation Details Date: December 10, 2025Time: 9:05 a.m. ETFormat: Corporate OverviewRegistration Link: https://goto.webcasts.com/starthe

BELLEVUE, Wash., Nov. 21, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), today announced that Vaximm AG, an OSR Company, has entered into a non-binding term sheet with BCM Europe AG ("BCME"), a Swiss-based life sciences investment group and OSRH's largest shareholder, to explore a potential exclusive global licensing agreement for VXM01, Vaximm's first-in-class oral cancer immunotherapy platform. The term sheet establishes a six-month exclusivity period during which Vaximm and BCME intend to negotiate and finalize a definitive licensing agreement, subject to customary

BELLEVUE, Wash., Nov. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH) today announced the appointment of Dr. Andreas Niethammer, M.D., Ph.D., Vaximm AG's Chief Medical Offer and scientific co-founder, as Chief Executive Officer (CEO), effective December 1, 2025. Vaximm is a Swiss-German biotech company developing oral T-cell immunotherapies for cancer and a subsidiary of OSR Holdings, Inc. Dr. Niethammer, an internationally recognized oncology expert, co-founded Vaximm to translate his pioneering work at The Scripps Research Institute, where he first described the co

BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO). This appointment strategically strengthens Vaximm's leadership with deep, long-standing expertise in the company's core technology. Dr. Wieckowski brings multidisciplinary experience spanning immunology and advanced data science, a profile uniquely poised to integrate reproducible analytical workflows and data-driven strategies to acc

BELLEVUE, Wash., Nov. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH) today announced the appointment of Dr. Andreas Niethammer, M.D., Ph.D., Vaximm AG's Chief Medical Offer and scientific co-founder, as Chief Executive Officer (CEO), effective December 1, 2025. Vaximm is a Swiss-German biotech company developing oral T-cell immunotherapies for cancer and a subsidiary of OSR Holdings, Inc. Dr. Niethammer, an internationally recognized oncology expert, co-founded Vaximm to translate his pioneering work at The Scripps Research Institute, where he first described the co

BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. . Dr. Niethammer is an internationally recognized oncology expert with over two decades

BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline. Dr. Höfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions a